Audentes Therapeutics Inc (NASDAQ:BOLD) CEO Matthew R. Patterson Sells 12,952 Shares
Audentes Therapeutics Inc (NASDAQ:BOLD) CEO Matthew R. Patterson sold 12,952 shares of the stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $40.00, for a total transaction of $518,080.00. Following the transaction, the chief executive officer now owns 12,952 shares of the company’s stock, valued at approximately $518,080. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of BOLD stock traded up $0.56 during trading hours on Friday, reaching $27.69. The stock had a trading volume of 1,699,736 shares, compared to its average volume of 424,443. Audentes Therapeutics Inc has a 12 month low of $24.51 and a 12 month high of $46.18. The firm has a market capitalization of $1.48 billion, a P/E ratio of -8.14 and a beta of 0.73.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.07). Analysts anticipate that Audentes Therapeutics Inc will post -3.33 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Sofinnova Ventures Inc purchased a new stake in Audentes Therapeutics in the first quarter valued at approximately $41,478,000. Redmile Group LLC raised its stake in Audentes Therapeutics by 70.3% in the second quarter. Redmile Group LLC now owns 2,228,656 shares of the biotechnology company’s stock valued at $85,157,000 after purchasing an additional 920,130 shares in the last quarter. BlackRock Inc. raised its stake in Audentes Therapeutics by 44.3% in the first quarter. BlackRock Inc. now owns 1,960,404 shares of the biotechnology company’s stock valued at $58,910,000 after purchasing an additional 601,906 shares in the last quarter. Partner Fund Management L.P. purchased a new stake in Audentes Therapeutics in the second quarter valued at approximately $16,254,000. Finally, Foresite Capital Management III LLC purchased a new stake in Audentes Therapeutics in the first quarter valued at approximately $9,476,000. Institutional investors own 96.74% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Recommended Story: What are Closed-End Mutual Funds?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.